Comparing the current results to its competitors, Cadrenal Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 19.96 %, recorded in the same quarter.
Cadrenal Therapeutics Inc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 3.17 %
Cadrenal Therapeutics Inc's Comment on Competition and Industry Peers
The competitive landscape includes products such as heparin, low molecular weight heparin, direct thrombin antagonists (bivalirudin and argatroban), and direct Xa inhibitors (fondaparinux), marketed by major pharmaceutical and generic companies. Additional competitors include academic institutions, government agencies, and other public and private research organizations engaged in research, patent protection, and collaborative efforts for similar drugs. The company has acquired intellectual property from eXIthera, comprising U.S. and foreign patents and applications related to Factor XIa inhibitors. The company estimates the peak annual U.S. market revenue potential for CAD-1005 in patients with heparin-induced thrombocytopenia (HIT) at approximately $825 million, as well as combined peak annual U.S. market revenue potential for tecarfarin and frunexian in patients with orphan and high-risk cardiovascular conditions. The company recognizes risks associated with intellectual property protection and competition that may impact its competitive position.
December 31, 2024
PONTE VEDRA, Fla. Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has recently delivered a comprehensive year-end update for 2024, illuminating its ambitious vision for the investigational drug tecarfarin. As a pioneering effort in the realm of anticoagulation therapy, tecarfarin aims to set a new standard of care for warfarin-dependent patients utilizing implanted cardiac devices, particularly those with left ventricular assist devices (LVAD) and other rare cardiovascular conditions.2024 has proven to be a year of substantial achievements for Cadrenal Therapeutics, underscoring its commitment to clinical excellence. The company has laid out a clear pathway for advancing tecarfarin towards becoming a superior a...
Provectus Biopharmaceuticals Inc's business model involves the development and commercialization of innovative therapies in the biopharmaceutical industry.
Rain Therapeutics Inc is a biopharmaceutical company that focuses on discovering and developing precision oncology therapies. Their business model revolves around identifying genetic alterations and biomarkers in cancer patients, and then developing targeted therapies to address these specific alterations. By tailoring treatments to individual patients, they aim to improve outcomes and provide more effective and personalized cancer care.
Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Sources:
Cadrenal Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cadrenal Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
